Terms: = Liver cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Diagnosis
15 results:
1. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring fgfr2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
Parisi A; Delaunay B; Pinterpe G; Hollebecque A; Blanc JF; Bouattour M; Assenat E; Ben Abdelghani M; Sarabi M; Niger M; Vivaldi C; Mandalà M; Palloni A; Bensi M; Garattini SK; Tougeron D; Combe P; Salati M; Rimini M; Cella CA; Tucci M; Diana A; Mori E; Longarini R; Artru P; Roth G; Evesque L; Vienne A; Turpin A; Hiret S; Bourgeois V; Herve C; Paulon R; Stacoffe M; Malka D; Neuzillet C; Edeline J; Lievre A; Guimbaud R; Chapda MCP; Rimassa L; Giampieri R; Valle J; Berardi R; Fares N
Eur J Cancer; 2024 Mar; 200():113587. PubMed ID: 38340384
[TBL] [Abstract] [Full Text] [Related]
2. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
[TBL] [Abstract] [Full Text] [Related]
3. New Options for Systemic Therapies in Intrahepatic Cholangiocarcinoma (iCCA).
Becht R; Wasilewicz MP
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374378
[TBL] [Abstract] [Full Text] [Related]
4. Acteoside (Verbascoside): A Prospective Therapeutic Alternative against Hepatocellular Carcinoma by Inhibiting the Expression of AXL, FGFR, BRAF, TIE2 and RAF1 Targets.
Kityania S; Nath R; Nath D; Patra JK; Talukdar AD
Comb Chem High Throughput Screen; 2023; 26(10):1907-1919. PubMed ID: 36321230
[TBL] [Abstract] [Full Text] [Related]
5. Gastric carcinosarcoma with fgfr2 amplification under long-term control with pazopanib: a case report and literature review.
Hayashi H; Makiyama A; Okumura N; Yasufuku I; Saigo C; Takeuchi T; Miyazaki T; Tanaka Y; Matsuhashi N; Murase K; Takahashi T; Futamura M; Yoshida K
BMC Gastroenterol; 2022 Jul; 22(1):360. PubMed ID: 35902814
[TBL] [Abstract] [Full Text] [Related]
6. [Current Studies and Evidence in Cholangiocarcinoma].
Zimpel C; Mitzlaff K; Jasper NA; Marquardt JU
Zentralbl Chir; 2022 Aug; 147(4):389-397. PubMed ID: 35863357
[TBL] [Abstract] [Full Text] [Related]
7. Infigratinib for cholangiocarcinoma.
Sadeghi S
Drugs Today (Barc); 2022 Jul; 58(7):327-334. PubMed ID: 35851868
[TBL] [Abstract] [Full Text] [Related]
8. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
Zen Y
Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
[TBL] [Abstract] [Full Text] [Related]
9. Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring
Beri N
Future Oncol; 2022 Apr; 18(11):1391-1402. PubMed ID: 35081733
[TBL] [Abstract] [Full Text] [Related]
10. Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population.
Lin S; Mo H; Li Y; Guan X; Chen Y; Wang Z; Xu B
BMC Cancer; 2021 Dec; 21(1):1330. PubMed ID: 34906122
[TBL] [Abstract] [Full Text] [Related]
11. Comparison of hepatic epithelioid angiomyolipoma and non-hepatitis B, non-hepatitis C hepatocellular carcinoma on contrast-enhanced ultrasound.
Tan Y; Xie XY; Li XJ; Liu DH; Zhou LY; Zhang XE; Lin Y; Wang W; Wu SS; Liu J; Huang GL
Diagn Interv Imaging; 2020 Nov; 101(11):733-738. PubMed ID: 32331793
[TBL] [Abstract] [Full Text] [Related]
12. [Recent progress in molecular targeted therapies for intrahepatic cholangiocarcinoma].
Xie ZH; Li J; Xia Y; Shen F
Zhonghua Wai Ke Za Zhi; 2020 Apr; 58(4):289-294. PubMed ID: 32241059
[TBL] [Abstract] [Full Text] [Related]
13. Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna liver Oncology Group.
Leoni S; Piscaglia F; Serio I; Terzi E; Pettinari I; Croci L; Marinelli S; Benevento F; Golfieri R; Bolondi L
Dig Liver Dis; 2014 Jun; 46(6):549-55. PubMed ID: 24630947
[TBL] [Abstract] [Full Text] [Related]
14. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease.
Murphy SK; Yang H; Moylan CA; Pang H; Dellinger A; Abdelmalek MF; Garrett ME; Ashley-Koch A; Suzuki A; Tillmann HL; Hauser MA; Diehl AM
Gastroenterology; 2013 Nov; 145(5):1076-87. PubMed ID: 23916847
[TBL] [Abstract] [Full Text] [Related]
15. In-hospital mortality from liver resection for hepatocellular carcinoma: a simple risk score.
Simons JP; Ng SC; Hill JS; Shah SA; Zhou Z; Tseng JF
Cancer; 2010 Apr; 116(7):1733-8. PubMed ID: 20143433
[TBL] [Abstract] [Full Text] [Related]
